

C2
11. (Amended) An isolated polypeptide comprising at least 25% of the amino acid sequence set forth in SEQ ID NO:4, wherein said isolated polypeptide exhibits morphogenesis activity.

REMARKS

Claims 9 and 11 are amended in order to better recite the patentable novelty of the present invention. Support for the amendment is found in the specification at page 48, lines 14-24 and page 49, lines 21-23. Accordingly, no new matter has been added.

In the December 18, 2002 Office Action, the Examiner noted that Applicants inadvertently failed to "address the 'scope' portion of the enablement rejection (Paper 9, 1/16/02, pages 9-10)." The undersigned apologizes for this oversight and has above amended the claims in order to address the Examiner's concerns.

Regarding a formal matter, please change the correspondence address herein to:


FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

In view of the above amendments and remarks, Applicants submit that the issue raised in papers Nos. 9 and 11 are overcome and the claims are now in allowable condition. Accordingly, reconsideration and allowance of this application is earnestly solicited.

Claims 7-16 remain presented for continued prosecution, with rejoinder of claims 13-16 being respectfully requested.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Lawrence S. Perry", with a long horizontal flourish extending to the right.

Attorney for Applicants
Lawrence S. Perry
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200



Application No. 09/622,522
Attorney Docket No. 01997.013500

VERSION WITH MARKINGS TO SHOW CHANGES MADE TO CLAIMS

9. (Amended) A fragment of a human polypeptide consisting of at least contiguous 20 amino acids from the amino acid sequence set forth in SEQ ID NO:4, wherein said amino acid fragment [comprises 20 or more contiguous amino acid residues of the amino acid sequence set forth in SEQ ID NO:4] exhibits morphogenesis activity.

11. (Amended) An isolated polypeptide comprising at least 25% of [the length of a human polypeptide consisting of] the amino acid sequence set forth in SEQ ID NO:4, wherein said isolated polypeptide exhibits morphogenesis activity.

NY_MAIN 320624v1

RECEIVED
JAN 22 2003
TECH CENTER 1600/2900